Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × Alpelisib × Clear all

NCT04216472 2025-09-30

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Phase 2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms